首页> 外文期刊>Tumori. >Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
【24h】

Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.

机译:肺癌和间皮瘤门诊中至大剂量顺铂为基础的化疗的短期水合作用和肾毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS AND BACKGROUND: Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen. In our Institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment. METHODS AND STUDY DESIGN: To assess incidence of cisplatin nephrotoxicity using a short hydration regimen, which included 2000 ml of fluids with control of diuresis, individual outpatient data was pooled retrospectively from patients enrolled in large randomized studies regarding cisplatin-based chemotherapy in lung cancer and mesothelioma. From February 1999 to November 2002, 107 patients treated with cisplatin (> or = 75 mg/m2/cycle) were examined, monitoring serum creatinine and creatinine clearance levels. RESULTS: Five patients out of 107 (4.6%) were withdrawn from chemotherapy because of renal toxicity. For the other 102 patients, serum creatinine and creatinine clearance measurements were stable around the normal values during treatment. No time trends relating to serum creatinine levels or creatinine clearance and cycle numbers or cisplatin-cumulative doses were detected (P = 0.36 and P = 0.64, for the relationship with cycle number, and P = 0.39 and P = 0.65 for the relationship with cumulative dose, respectively, random effect model) after adjusting for the total number of cycles administered. CONCLUSIONS: These observations indicate that intermediate to high-dose cisplatin administration is feasible in outpatient management with a short hydration regimen without high risk of nephrotoxicity.
机译:目的和背景:顺铂是多种肿瘤联合化疗的标准成分,具有重要的抗肿瘤特性,但也具有多种毒性作用。特别地,主要的剂量限制作用似乎是肾毒性。在一些国家,为减少顺铂给药后的肾毒性,建议在医院方案中进行化学疗法后进行24小时补液。在我们的机构中​​,顺铂化疗是一种门诊治疗,使用NaCl溶液加上速尿和治疗期间的利尿监测可提供充足的水分。方法和研究设计:为了评估使用短水合方案(包括2000 ml利尿控制液)的顺铂肾毒性的发生率,回顾性收集了来自大型随机研究的患者的门诊数据,这些患者涉及基于顺铂的肺癌和化疗间皮瘤。从1999年2月至2002年11月,对107例接受顺铂(≥75 mg / m2 /周期)治疗的患者进行了检查,监测血清肌酐和肌酐清除率。结果:107名患者中有5名(4.6%)因肾毒性而退出化疗。对于其他102例患者,在治疗期间血清肌酐和肌酐清除率的测量值稳定在正常值附近。没有检测到与血清肌酐水平或肌酐清除率,周期数或顺铂累积剂量有关的时间趋势(与周期数的关系为P = 0.36和P = 0.64,与累积值的关系为P = 0.39和P = 0.65剂量,随机效应模型)调整给药周期总数后。结论:这些观察结果表明,在短期水合作用且不存在肾毒性高风险的情况下,中至大剂量顺铂给药在门诊治疗中是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号